I learned the hard way that what you wear and what you sleep on matters
Ernie Blevins, an endocrinologist at the University of Washington, and his colleagues co-administered oxytocin and a low dose of tirzepatide, a dual agonist mimicking the effects of both GLP-1 and glucose-dependent insulinotropic polypeptide, to obese rats and discovered that together, they produced more pronounced weight loss than either treatment alone
Clinical trials have provided limited insight into the long-term effects, as the longest trials spanned less than six years in adults and about one year in adolescents
A muchos les resulta difcil continuar con el tratamiento con medicamentos GLP-1 Ya sea debido al alto costo, los efectos secundarios no deseados o ambos, la mayora de las personas que comienzan a usar medicamentos GLP-1 dejan de tomarlos antes de ver algn beneficio significativo para la salud
Those who completed the taper and discontinued medication did not regain significant weight over a six-month follow-up
Science 333 : 353357